- Home
- GROW vs NRSN Comparison
GROW vs NRSN Comparison
Compare GROW & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROW | NRSN |
|---|---|---|
| Founded | 1968 | 2017 |
| Country | United States | Israel |
| Employees | N/A | 15 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.3M | 28.4M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | GROW | NRSN |
|---|---|---|
| Price | $3.19 | $0.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 16.3K | ★ 172.0K |
| Earning Date | 05-07-2026 | 04-06-2026 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $23,850,609.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $63.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.05 | $0.68 |
| 52 Week High | $3.65 | $2.60 |
Technical Indicators
Market Signals| Indicator | GROW | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 50.84 | 38.70 |
| Support Level | $3.10 | $0.68 |
| Resistance Level | $3.43 | $1.30 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 34.46 | 15.27 |
Price Performance
Historical ComparisonAbout GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.